Oticon Own was released in Sept 22, so would be due a platform review in 2025.
This:
-
- The Royal National Institute for Deaf People (RNID) web statistics state that hearing loss affects more than 12 million people in the UK, and provides a breakdown of the prevalence of hearing loss by NHS and local authority area in the UK [RNID, 2020a].
-
A key RNID Hearing Matters report states that [RNID, 2020a]:
- There is evidence of an average delay of 10 years in people seeking help for their hearing loss. When people do seek help, GPs fail to refer 45% of people reporting hearing loss to NHS hearing services.
- Most people with hearing loss are aged over 50 years, and prevalence increases with age. It cites evidence from a previous Medical Research Council national study of hearing, which found:
- Hearing loss affects 41.7% of people over 50 in the UK, increasing to 71.1% of people over 70.
- With an increasingly ageing population, it is estimated that by 2035, over 15.6 million people in the UK (one-fifth of the population) will be affected by hearing loss.
- About 900,000 people have severe or profound deafness
Says that severe and profound will make up about 8% of the whole market in the U.K. - of those the split is bit under half who have a profound issue: given that many Severe losses can be fitted with power RIC/SP with mould. So a total potential UP market of 400,000 (say 75% penetration), divided by average replacement window of 6 years, so 50k (x2 assuming binaural fit) = £100k units divided by typical market share. (Sonova 31%, WDM 30% etc. )
That means even in a fairly well developed smaller economy, it’s worth 30k units or (NHS 25k X £100 + Private 5k X £500), which doesn’t really go that far at the product development level. I appreciate these are estimated values and penetration figures might be wrong (though monaural wearing of aids is more historically established here).
Now, I’m not for one minute saying they should ignore profound losses, but in terms of the market share and product development the non-RIC market sits squarely at the sides of the bell curve. It’s not surprising that all manufacturers who are looking at the challenge of OTC are focussing on the 90% of the market with the faster turnover and easier fits.